|
Low vemurafenib plasma exposure as a short-term predictive parameter of progression disease in metastatic BRAFV600mut melanoma. |
|
|
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche Pharma AG |
|
|
Honoraria - Roche Pharma AG |
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche Pharma AG |
|
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis |
Travel, Accommodations, Expenses - Roche |